COCogent Biosciences, Inc. COGT · NASDAQ
$30.01 +1.66% (+$0.49)
- Market cap
- $5.21B
- Enterprise value
- $5.27B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -50.1%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.31
- Free float
- 89.8%
About the company
Cogent Biosciences, Inc. (COGT) is an American biotechnology company focused on the development of innovative therapeutics for patients with oncological and genetic diseases. With a primary emphasis on targeted therapy and gene therapy, Cogent Biosciences aims to provide effective and personalized treatments. Their research and development efforts are centered on identifying new therapeutic targets and discovering innovative approaches to treatment. The shares of Cogent Biosciences, Inc. (COGT) may be suitable for investors seeking opportunities in the field of biotechnology and innovative therapeutics with potential in oncology and genetic diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew R. Robbins
Employees
258
Headquarters
Waltham
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number